The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.
The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.
Transcript (slightly modified)
Are the oncology practices using COME HOME better equipped to fulfill requirements for the Quality Payment Program?
I believe that that is the main value of COME HOME. The processes that we’ve put in place with the triage pathways, where we give nurses the power of the schedule and a decision support tool to be able to make sure that they’re making the decisions that their physicians would want made, getting patients into the office for same-day visits, that’s what worked in COME HOME to cut down hospitalization rates.
Patients do better when they’re not in the hospital. Every time a patient goes into the hospital, they come out just a little less quality of life than they went in. They’re just not as strong or they got a bad infection or something else happened. So by keeping patients out of the hospital, we keep them healthier, which is the main goal, but we also save that money. That’s the low-hanging fruit.
The processes we created with COME HOME have allowed us to do multiple same-day visits and in my practice, we’ve cut our hospital admissions by over half, and that’s significant. It’s also significant not only for patient quality of life but for physician quality of life. If I don’t have so many people to round on in the hospital before I go to the office to do the day’s work, I can manage them much more easily.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More